Serological response to influenza vaccination among adults hospitalized with community-acquired pneumonia

• Type of Material: Article
• Authors: Caroline Quinn Pratt, Emory University; Yuwei Zhu, Vanderbilt University; Carlos G. Grijalva, Vanderbilt University; Richard G. Wunderink, Northwestern University; D. Mark Courtney, Northwestern University; Grant Waterer, Northwestern University; Min Z Levine, Centers for Disease Control and Prevention; Stacie Jefferson, Centers for Disease Control and Prevention; Wesley H. Self, Vanderbilt University; Derek J. Williams, Vanderbilt University; Lynn Finelli, Centers for Disease Control and Prevention; Anna M. Bramley, Centers for Disease Control and Prevention; Kathryn M. Edwards, Vanderbilt University; Seema Jain, Centers for Disease Control and Prevention; Evan Anderson, Emory University
• Language: English
• Date: 2019-03-01
• Publisher: Wiley Open Access
• Publication Version: Final Published Version
• Copyright Statement: © 2018 The Authors.
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1111/irv.12622
• Title of Journal or Parent Work: Influenza and Other Respiratory Viruses
• ISSN: 1750-2640
• Volume: 13
• Issue: 2
• Start Page: 208
• End Page: 212
• Grant/Funding Information: Supported by the Influenza Division, National Center for Immunization and Respiratory Diseases, CDC through cooperative agreements with each study site.
• Keywords: Infectious Diseases; SAFETY; Science & Technology; Virology; IMMUNE-RESPONSE; EFFICACY; IMMUNOGENICITY; Life Sciences & Biomedicine
• Research Categories: Health Sciences, Immunology; Biology, Virology

Abstract

Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd. Ninety-five adults enrolled in the Etiology of Pneumonia in the Community study with negative admission influenza polymerase chain reaction (PCR) tests received influenza vaccination during hospitalization. Acute and convalescent influenza serology was performed. After vaccination, seropositive (≥1:40) hemagglutination antibody titers (HAI) were achieved in 55% to influenza A(H1N1)pdm09, 58% to influenza A(H3N2), 77% to influenza B (Victoria), and 74% to influenza B (Yamagata) viruses. Sixty-six (69%) patients seroconverted (≥4-fold HAI rise) to ≥1 strain. Failure to seroconvert was associated with diabetes, bacterial detection, baseline seropositive titers for influenza B (Yamagata), and influenza vaccination in the previous season.